Abbott Gets FDA’s Premarket Approval for Aveir VR Leadless Pacemaker

Abbott has received the FDA’s premarket approval for its Aveir single-chamber leadless pacemaker for patients with slow heart rhythms.

The device is implanted directly inside the heart's right ventricle via a minimally invasive procedure. It has a mapping capability that allows physicians to measure electrical signals within the heart to determine the correct placement of the device before final implantation.

The pacemaker features an extended battery life that can be up to two times longer than other commercially available leadless pacemakers, the company said.